Profil
Keith A.
Vendola worked as Senior Director of Business Development at Threshold Pharmaceuticals, Head of Corporate Development at DiObex, Vice President of Finance and Corporate Development at Eiger BioPharmaceuticals, Chief of Staff and VP of Competitive Strategy at Coherus BioSciences, Chief Strategy Officer at Rezolute, and Chief Financial Officer at IO Biotech.
He received his undergraduate degree from the College of the Holy Cross, his doctorate from Dartmouth Medical School, and his MBA from Kellogg School of Management.
Anciens postes connus de Keith Vendola
| Sociétés | Poste | Fin |
|---|---|---|
| IO BIOTECH, INC. | Directeur Financier/CFO | 09/05/2022 |
| REZOLUTE, INC. | Directeur Financier/CFO | 06/11/2020 |
| COHERUS BIOSCIENCES, INC. | Responsable des Ressources Humaines | 01/06/2017 |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Directeur Financier/CFO | - |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | - |
Formation de Keith Vendola
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| Dartmouth Medical School | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REZOLUTE, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| IO BIOTECH, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
DiObex, Inc.
 DiObex, Inc. Pharmaceuticals: MajorHealth Technology DiObex, Inc. develops therapies for metabolic disease treatment. Its products address the markets for the treatment of diabetes and its co-morbidities such as hypertension, dyslipidemia, and visceral adiposity. The company was founded in 2003 and is headquartered in San Francisco, CA. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
